Department Of Pharmaceutical Sciences and Natural Products

Permanent URI for this communityhttps://kr.cup.edu.in/handle/32116/52

Browse

Author: search.filters.author.Kumar, Deepak

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective
    (MDPI, 2023-02-15T00:00:00) Kumar, Adarsh; Singh, Ankit Kumar; Singh, Harshwardhan; Vijayan, Veena; Kumar, Deepak; Naik, Jashwanth; Thareja, Suresh; Yadav, Jagat Pal; Pathak, Prateek; Grishina, Maria; Verma, Amita; Khalilullah, Habibullah; Jaremko, Mariusz; Emwas, Abdul-Hamid; Kumar, Pradeep
    Cancer is one of the major healthcare challenges across the globe. Several anticancer drugs are available on the market but they either lack specificity or have poor safety, severe side effects, and suffer from resistance. So, there is a dire need to develop safer and target-specific anticancer drugs. More than 85% of all physiologically active pharmaceuticals are heterocycles or contain at least one heteroatom. Nitrogen heterocycles constituting the most common heterocyclic framework. In this study, we have compiled the FDA approved heterocyclic drugs with nitrogen atoms and their pharmacological properties. Moreover, we have reported nitrogen containing heterocycles, including pyrimidine, quinolone, carbazole, pyridine, imidazole, benzimidazole, triazole, ?-lactam, indole, pyrazole, quinazoline, quinoxaline, isatin, pyrrolo-benzodiazepines, and pyrido[2,3-d]pyrimidines, which are used in the treatment of different types of cancer, concurrently covering the biochemical mechanisms of action and cellular targets. � 2023 by the authors.
  • No Thumbnail Available
    Item
    Efficacy of p-coumaric acid in chronic constriction injury induced neuropathic pain in rats
    (Indian Drug Manufacturers' Association, 2021-12-14T00:00:00) Bharti, Akash; Kaur, Jaspreet; Kumar, Amit; Singh, Simranjit; Kumar, Deepak
    The present research work has been designed to evaluate the effect of p-coumaric acid in chronic constriction injury (CCI) of sciatic nerve induced neuropathic pain in rats. In addition, biochemical tests such as thiobarbituric acid reactive substances (TBARS), reduced glutathione (GSH) and total protein were performed in sciatic nerve tissue sample. The neuropathic pain has been effi ciently and successfully induced in rat by the performance of CCI. The battery of behavioural test showed the development of neuropathic pain as an index of rising the paw and tail thermal and mechanical pain sensitivity. The treatment of p-coumaric acid at dose 50 and 100 mg kg-1, p.o. for 15 consecutive days have been shown to produce signifi cant ameliorative effect on CCI of sciatic nerve induced neuropathic pain sensitivity. In addition, CCI of sciatic nerve also induces the oxidative stress in nervous system by rising TBARS, decrease GSH and proteins levels in sciatic nerve tissue and these effects are reversed via administration of p-coumaric acid and statistically equivalent to standard drug. Hence, it may be concluded that, p-coumaric acid can be useful in the management of neuropathic pain symptoms. � 2021 Indian Drug Manufacturers' Association. All rights reserved.